Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments

Toxicon

Volumn 43, Issue 3, 2004, Pages 233-241

  Aubrey, Nicolas ^a,d   Muzard, Julien ^a   Peter, Jean Christophe ^c   Rochat, Hervé ^b   Goyffon, Max ^a   Devaux, Christiane ^b   Billiald, Philippe ^a,d  

^a MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^b CNRS   (France)

^c INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d CEMAGREF   (France)

Author keywords

Androctonus australis; Antibody engineering; Antivenom; Immunotherapy; Scorpion; Toxin

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; NEUROTOXIN; NEUROTOXIN AAHI; NEUROTOXIN AAHIII; NEUTRALIZING ANTIBODY; PAPAIN; SCORPION VENOM; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANDROCTONUS AUSTRALIS; ANIMAL CELL; ANTIBODY ENGINEERING; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ENVENOMATION; FEMALE; HYBRIDOMA CELL CULTURE; IMMUNOTHERAPY; LETHALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCORPION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; DNA PRIMERS; ESCHERICHIA COLI; FEMALE; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEUROTOXINS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCORPION VENOMS;

ANDROCTONUS; ANDROCTONUS AUSTRALIS; EQUIDAE; MURINAE; SCORPIONES;

EID: 1642389249     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2003.11.024     Document Type: Article

References (39)

1. Abroug F., El-Atrous S., Nouira S., Haguiga H., Touzi N., Bouchoucha S. Serotherapy in scorpion envenomation: a randomised controlled trial. Lancet. 354:1999;906-909.
2. Andris-Widhopf J., Rader C., Steinberger P., Fuller R., Barbas C.F. 3 rd. Methods for the generation of chiken monoclonal antibody fragments by phage display. J. Immunol. Meth. 242:2000;159-181.
3. Aubrey N., Devaux C., di Luccio E., Goyffon M., Rochat H., Billiald P. A recombinant scFv/streptavidin-binding peptide fusion protein for the quantitative determination of the scorpion venom neurotoxin AahI. Biol. Chem. 382:2001;1621-1628.
4. Aubrey N., Devaux C., Sizaret P.Y., Rochat H., Goyffon M., Billiald P. Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin. Cell. Mol. Life Sci. 60:2003;617-628.
5. Boder E.T., Midelfort K.S., Wittrup K.D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl Acad. Sci. USA. 97:2000;10701-10705.
6. Bond G.R. Antivenin administration for centruroides scorpion sting - risks and benefits. Ann. Emerg. Med. 21:1992;788-791.
7. Chapman A.P., Antoniw P., Spitali M., West S., Stephens S., King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17:1999;780-783.
8. Chippaux J.P., Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon. 36:1998;823-846.
9. Clot-Faybesse O., Juin M., Rochat H., Devaux C. Monoclonal antibodies against the Androctonus australis hector scorpion neurotoxin I: characterisation and use for venom neutralisation. FEBS Lett. 458:1999;313-318.
10. Darling A. Validation of biopharmaceutical purification processes for virus clearance and evaluation. Mol. Biotechnol. 21:2002;57-83.
11. Devaux C., Clot-Faybesse O., Juin M., Mabrouk K., Sabatier J.M., Rochat H. Monoclonal antibodies neutralizing the toxin II from Androctonus australis hector scorpion venom: usefulness of a synthetic, non-toxic analog. FEBS Lett. 412:1997;456-460.
12. Devaux C., Moreau E., Goyffon M., Rochat H., Billiald P. Construction and functional evaluation of a single-chain antibody fragment that neutralizes toxin AahI from the venom of the scorpion Androctonus australis hector. Eur. J. Biochem. 268:2001;694-702.
13. El Hafny B., Chgoury F., Adil N., Cohen N., Hassar M. Intraspecific variability and pharmacokinetic characteristics of Androctonus mauretanicus mauretanicus scorpion venom. Toxicon. 40:2002;1609-1616.
14. Genetta T.B., Mauro V.F. ABCIXIMAB: a new antiaggregant used in angioplasty. Ann. Pharmacother. 30:1996;251-257.
15. Glennie M.J., Johnson P.W. Clinical trials of antibody therapy. Immunol. Today. 21:2000;403-410.
16. Hugo N., Weidenhaupt M., Beukes M., Xu B., Janson J.C., Vernet T., Altschuh D. VL position 34 is a key determinant for the engineering of stable antibodies with fast dissociation rates. Protein Engng. 16:2003;381-386.
17. Huston J.S., George A.J. Engineered antibodies take center stage. Hum. Antibodies. 10:2001;127-142.
18. Ismail M., Abd-Elsalam M.A. Pharmacokinetic of 125I-labelled IgG, F(ab)′2 and Fab fractions of scorpion and snake antivenins: merits and potential for therapeutic use. Toxicon. 36:1998;1523-1528.
19. Krifi M.N., Amri F., Kharrat H., El Ayeb M. Evaluation of antivenom therapy in children severely envenomed by Androctonus australis garzonii (Aag) and Buthus occitanus tunetanus (Bot) scorpions. Toxicon. 37:1999;1627-1634.
20. Little M., Kipriyanov S.M., Le Gall F., Moldenhauer G. Of mice and men: hybridoma and recombinant antibodies. Immunol. Today. 21:2000;364-370.
21. Martin-Eauclaire M.F., Couraud F. Scorpion neurotoxins: effects and mechanisms. Chang L.W., Dyer R.S. Handbook of Neurotoxicity. 1995;683-716 Marcel Dekker, New York.
22. Maynard J.A., Maassen C.B., Leppla S.H., Brasky K., Patterson J.L., Iverson B.L., Georgiou G. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20:2002;597-601.
23. Merienne K., Germain N., Zinn-Justin S., Boulain J.C., Ducancel F., Ménez A. The functional architecture of an acetylcholine receptor-mimicking antibody. J. Biol. Chem. 272:1997;23775-23783.
24. Mousli M., Devaux C., Rochat H., Goyffon M., Billiald P. A recombinant single-chain antibody fragment that neutralizes toxin II from the venom of the scorpion Androctonus australis hector. FEBS Lett. 442:1999;973-980.
25. Muller R. Calculation of average antibody affinity in anti-hapten sera from data obtained by competitive radioimmunoassay. J. Immunol. Meth. 34:1980;345-352.
26. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., Sheridan R., Blake R., Smith L.A., Marks J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl Acad. Sci. USA. 99:2002;11346-11350.
27. Peter J.C., Eftekhari P., Billiald P., Wallukat G., Hoebeke J. scFv single chain antibody variable fragment as inverse agonist of the b2-adrenergic receptor. J. Biol. Chem. 278:2003;36740-36747.
28. Possani L. Antivenom for scorpion sting. Lancet. 355:2000;67-68.
29. Pugsley A.P. The complete general secretory pathway in gram-negative bacteria. Microbiol. Rev. 57:1993;50-108.
30. Renard M., Belkadi L., Hugo N., England P., Altschuh D., Bedouelle H. Knowledge-based design of reagentless fluorescent biosensors from recombinant antibodies. J. Mol. Biol. 318:2002;429-442.
31. Richalet-Secordel P.M., Rauffier-Bruyere N., Christensen L.L., Ofenloch-Haehnle B., Seidel C., van Regenmortel M.H. Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. Anal. Biochem. 249:1997;165-173.
32. Rochat H., Tessier M., Miranda F., Lissitzky S. Radioiodination of scorpion and snake toxins. Anal. Biochem. 82:1977;532-548.
33. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning. A laboratory manual. Second ed:1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
34. Schillberg S., Fischer R., Emans N. Molecular farming of recombinant antibodies in plants. Cell. Mol. Life Sci. 60:2003;433-445.
35. Sofer S., Shahak E., Gueron M. Scorpion envenomation and antivenom therapy. J. Pediatr. 124:1994;973-978.
36. Tan P., Mitchell D.A., Buss T.N., Holmes M.A., Anasetti C., Foote J. Superhumanized antibodies: reduction of immunogenic potential by complementary-determining region grafting with human germline sequences: application to an anti-CD28. J. Immunol. 169:2002;1119-1125.
37. Theakston R.D., Warrell D.A., Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon. 41:2003;541-557.
38. Thullier P., Lafaye P., Mégret F., Deubel V., Jouan A., Mazié J.C. A recombinant Fab neutralizes dengue virus in vitro. J. Biotechnol. 69:1999;183-190.
39. Worn A., Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305:2001;989-1010.